|
Koshkin A.M., Pokrovskaya A.V.
Two-drug antiretroviral therapy regimen with dolutegravir and lamivudine for previously untreated HIV-infected patients
|
№3 / 2023
|
|
Matievskaya N.V., Dolinskaya O.V.
Experience with a dual ART regimen in an elderly female patient with HIV infection
|
№4 / 2021
|
|
Sizova N.V., Korneeva T.S., Bratkova V.V., Sotnikova A.L., Rassokhin V.V.
Combined antiretroviral drugs containing lamivudine and zidovudine for the treatment of HIV infection
|
№1 / 2017
|
|
Ivanova E.S.
Phosphaside and lamivudine as a nucleoside base of first-line antiretroviral therapy regimens for HIV infection
|
№4 / 2016
|
|
Kozyrina N.V., Yurin O.G.
A virologic response as a hallmark of excellence: TDF/FTC or TDF/3TC
|
№6 / 2015
|
|
Kozhevnikova G.М., Efremova O.S., Jallolu Abdurahman
Pharmacoeconomical analysis of antiretroviral therapy in patients with HIV and hepatitis B virus co-infection
|
№2 / 2015
|
|
Kozyrina N.V., Narsia R.S., Yurin O.G.
Abacavir and lamivudine as a nucleoside base of antiretroviral therapy
|
№5 / 2014
|
|
Pyadushkina E.A., Andreeva N.S., Omelyanovsky V.V., Avxentyeva M.V., Rebrova O.Yu.
Сlinicoeconomic analysis of the use of kivexa in the first-line antiretroviral therapy of HIV infection in the Russian Federation
|
№3 / 2013
|
|
Lopatkina T.N., Abdurakhmanov D.T., Volchkova E.V., Tanashchuk E.L.
Entecavir in the treatment of reactivation of hepatitis B virus infection in chemotherapy for B-cell lymphoma
|
№5 / 2012
|
Русский
